+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 80Years
All Genders
ID07111455

Study on Changes in Oral Microbiome in Adults With Locally Advanced Oral Squamous Cell Carcinoma After Neoadjuvant Chemoimmunotherapy

Led by Zhujiang Hospital · Updated on 2025-09-23

32

Participants Needed

1

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating how changes in the oral microbiome relate to tumor markers in patients with locally advanced oral squamous cell carcinoma LA-OSCC after receiving neoadjuvant chemoimmunotherapy. This study aims to understand the implications of these changes for treatment effectiveness, resistance to chemotherapy, and predicting patient outcomes. The study is observational and sponsored by Zhujiang Hospital. Participants will receive two cycles of intravenous neoadjuvant treatment consisting of Tislelizumab 200 mg every three weeks, combined with chemotherapy drugs Paclitaxel, Cisplatin, or Carboplatin administered intravenously during each three-week cycle. This treatment schedule is planned for two cycles before further evaluation. During the study, participants will be monitored for their response to treatment at eight weeks using the Objective Response Rate. Researchers will also track longer-term outcomes including overall survival and progression-free survival over two years. Assessments will include blood tests and evaluations of organ function to ensure participants can tolerate treatment. The total study duration extends through follow-up periods up to two years to assess treatment impact and prognosis.

CONDITIONS

Brief Title

Prospective Cohort Study on Oral Microbiome Changes in Patients With Locally Advanced Oral Squamous Cell Carcinoma Following Neoadjuvant Chemoimmunotherapy

Research Team

X

Xiaozhi LV

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here